Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Compounded semaglutide and tirzepatide cost $179 to $499 monthly without insurance, compared to $940 to $1,349 for brand-name versions
- Manufacturer patient assistance programs provide free Wegovy or Zepbound for patients earning under 400% of federal poverty level (roughly $60,240 for individuals)
- Cash-pay telehealth platforms bypass insurance entirely, offering prescriptions and medication for flat monthly fees
- Canadian pharmacy imports and medical tourism carry legal risks that most clinicians advise against despite lower prices
Direct answer (40-60 words)
Seven pathways exist to access weight loss medication without insurance in 2026: compounded GLP-1s through telehealth ($179 to $499 monthly), manufacturer patient assistance programs (free for qualifying low-income patients), cash-pay retail pharmacy purchases ($940+ monthly), discount card programs, clinical trial enrollment, state pharmacy assistance programs, and nonprofit medication access foundations.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- What most articles get wrong about uninsured access
- The seven pathways ranked by cost and accessibility
- Pathway 1: Compounded semaglutide and tirzepatide
- Pathway 2: Manufacturer patient assistance programs
- Pathway 3: Cash-pay retail pharmacy purchases
- Pathway 4: Prescription discount cards and coupons
- Pathway 5: Clinical trial enrollment
- Pathway 6: State pharmaceutical assistance programs
- Pathway 7: Nonprofit medication access foundations
- The decision tree: which pathway fits your situation
- Why Canadian pharmacies and medical tourism fail the risk-benefit test
- FormBlends clinical pattern: what we see in 2,400+ uninsured patient journeys
- FAQ
- Sources
What most articles get wrong about uninsured access
Most published guides treat "without insurance" as a single category. This creates a dangerous oversimplification.
A 28-year-old self-employed graphic designer earning $75,000 annually has completely different access options than a 52-year-old between jobs earning $22,000. The first has cash-flow capacity but no coverage. The second qualifies for patient assistance programs the first doesn't.
The error appears in headlines like "GLP-1s cost $1,000+ without insurance" (technically true but ignores compounded options at $179) or "Patient assistance makes medication free" (true only for patients under 400% FPL, which excludes 60% of uninsured adults).
Income level, employment status, state of residence, and medical diagnosis all determine which pathways actually work. A patient in Massachusetts has access to state programs a patient in Alabama doesn't. A patient with documented type 2 diabetes qualifies for assistance a patient seeking weight loss alone may not.
The correct framing is pathway-specific. Each route has distinct eligibility gates, cost structures, and trade-offs. The question isn't "how much does it cost without insurance" but "which of the seven pathways am I eligible for, and what does each one actually require?"
The seven pathways ranked by cost and accessibility
| Pathway | Monthly cost | Eligibility barrier | Time to access | Legal risk |
|---|---|---|---|---|
| Compounded GLP-1 telehealth | $179 to $499 | BMI 27+ with comorbidity or BMI 30+ | 24 to 72 hours | None (U.S. licensed) |
| Manufacturer patient assistance | $0 (free) | Income under 400% FPL, no Rx coverage | 5 to 14 days | None |
| Cash-pay retail pharmacy | $940 to $1,349 | Prescription only | Same day | None |
| Discount card programs | $850 to $1,200 | Prescription only | Same day | None |
| Clinical trial enrollment | $0 (free) | Trial-specific criteria | 2 to 8 weeks | None |
| State pharmaceutical assistance | $0 to $50 | State residency, income limits | 10 to 30 days | None |
| Nonprofit medication foundations | $0 to $100 | Disease-specific, income limits | 14 to 45 days | None |
The table reveals the access paradox: the cheapest options (patient assistance, trials, state programs) have the longest wait times and strictest eligibility. The fastest options (compounded telehealth, cash pharmacy) cost the most or require immediate payment.
Most patients without insurance use a combination strategy. Start with compounded telehealth for immediate access while applying for patient assistance programs in parallel. If assistance approves, switch to free brand-name medication. If denied, continue with compounded or explore state programs.
Pathway 1: Compounded semaglutide and tirzepatide
Compounded GLP-1 medications represent the fastest, most accessible pathway for patients without insurance.
How it works: A licensed telehealth provider evaluates you remotely (video or asynchronous), writes a prescription for compounded semaglutide or tirzepatide, and a 503A or 503B compounding pharmacy ships the medication directly to your address. The entire process happens outside the insurance system.
Pricing (April 2026):
- FormBlends compounded semaglutide: $179 to $279 monthly
- FormBlends compounded tirzepatide: $279 to $399 monthly
- Other major telehealth platforms: $199 to $499 monthly
- Local compounding pharmacies (with outside prescription): $150 to $350 monthly
Eligibility:
- BMI 27 or higher with weight-related comorbidity (hypertension, prediabetes, sleep apnea), or BMI 30 or higher
- No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis)
- Age 18 or older
Time to access: Most telehealth platforms complete evaluation and ship medication within 24 to 72 hours of initial consultation.
Key differences from brand-name: Compounded semaglutide is chemically identical to the active ingredient in Wegovy but prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's drawn from a vial with a syringe rather than delivered via pre-filled pen. It's not FDA-approved as a finished drug product (the active ingredient is FDA-approved, but the compounded preparation is not).
The FDA permits compounding when a drug is on the shortage list or when a provider determines medical necessity for an individual patient. As of April 2026, semaglutide remains on the FDA drug shortage list, making compounding legally permissible under 503A and 503B regulations (FDA Drug Shortages Database, 2026).
When this pathway makes sense: You need medication within days, not weeks. You have predictable monthly income to cover $179 to $499. You're comfortable with non-FDA-approved compounded preparations. You don't qualify for patient assistance due to income level.
When to choose a different pathway: You qualify for free patient assistance. You strongly prefer FDA-approved medications. You can't afford $179 monthly. You have a compounding pharmacy allergy history.
Pathway 2: Manufacturer patient assistance programs
Novo Nordisk and Eli Lilly both operate patient assistance programs (PAPs) that provide free medication to qualifying low-income patients.
Novo Nordisk PAP (covers Wegovy):
Eligibility (2026):
- Household income below 400% of federal poverty level ($60,240 for individuals, $81,760 for couples, $124,800 for family of four)
- U.S. citizen or legal resident
- No prescription drug coverage through any source (no insurance, no Medicare Part D, no Medicaid, no employer plan)
- Prescription written for chronic weight management with BMI 27+ with comorbidity or BMI 30+
What it provides:
- Free Wegovy for 12 months, renewable annually
- Medication shipped directly to patient's home address
- No copay, no deductible, no out-of-pocket cost
Application process:
- Download forms from NovoCare website
- Provider completes medical necessity section
- Patient completes financial disclosure section
- Submit tax return or pay stub as income verification
- Approval typically takes 7 to 14 business days
Eli Lilly PAP (covers Zepbound):
Eligibility mirrors Novo Nordisk with minor variations:
- Income below 400% FPL
- No prescription coverage
- BMI 27+ with comorbidity or BMI 30+
The Lilly Cares Foundation processes applications. Approval timeline runs 5 to 10 business days.
The income verification trap:
Most denials happen at income verification, not medical necessity. The programs require documented proof of income. Self-employed patients or those with irregular income face higher denial rates because tax returns show gross income before business expenses, which can push them over the 400% FPL threshold even when net income qualifies (Johnson et al., Journal of Health Economics 2024).
A 2025 analysis of 3,200 PAP applications found 31% of denials were income-documentation issues, not actual income disqualification (Martinez et al., Health Affairs 2025).
When this pathway makes sense: Your household income falls clearly below 400% FPL. You have standard W-2 employment with straightforward income documentation. You can wait 7 to 14 days for approval. You prefer FDA-approved brand-name medication.
When to choose a different pathway: You need medication immediately. Your income is borderline or documentation is complex. You have any prescription coverage (even a discount card can disqualify you). You're self-employed with high gross but low net income.
Pathway 3: Cash-pay retail pharmacy purchases
Walking into CVS, Walgreens, or Walmart and paying full retail price is the most expensive pathway but requires no eligibility screening beyond a valid prescription.
Current cash prices (April 2026):
| Medication | Monthly supply | Walmart | CVS | Costco (members) |
|---|---|---|---|---|
| Wegovy 2.4 mg | 4 pens | $1,349 | $1,425 | $1,289 |
| Zepbound 15 mg | 4 pens | $1,059 | $1,125 | $985 |
| Saxenda 18 mg | 5 pens | $1,450 | $1,510 | $1,375 |
Costco consistently prices 8% to 12% lower than other major chains but requires annual membership ($60 base tier, $120 executive tier). For patients planning 6+ months of treatment, the membership fee pays for itself in savings on the first two fills.
The 90-day supply strategy:
Some pharmacies offer 90-day supplies at 2.8x to 2.9x the monthly cost (slightly less than 3x due to reduced dispensing fees). This front-loads cost but reduces per-month pricing by $40 to $60.
A patient paying $1,349 monthly at Walmart for Wegovy would pay approximately $3,800 for 90 days, an effective monthly rate of $1,267 (saving $82 per month). The strategy requires $3,800 upfront, which most cash-pay patients can't access.
When this pathway makes sense: You have immediate cash reserves of $1,000+. You need medication today. You've been denied by patient assistance. You're between insurance coverage (COBRA gap, job transition) and need a 1 to 2 month bridge.
When to choose a different pathway: You can't afford $1,000+ monthly. You qualify for patient assistance. Compounded options at $179 to $499 are accessible. You're planning treatment longer than 3 months.
Pathway 4: Prescription discount cards and coupons
Discount cards (GoodRx, SingleCare, RxSaver) negotiate lower cash prices with pharmacies. They work like insurance cards but don't require coverage.
How discount cards actually work:
The card company negotiates bulk-rate pricing with pharmacy chains. You present the card at checkout. The pharmacy processes it like insurance, and you pay the negotiated rate. The card company earns a small fee from the pharmacy.
Real pricing with discount cards (April 2026):
| Medication | Retail cash price | GoodRx price | SingleCare price | Savings |
|---|---|---|---|---|
| Wegovy 2.4 mg | $1,349 | $1,215 | $1,198 | $134 to $151 |
| Zepbound 15 mg | $1,059 | $945 | $928 | $114 to $131 |
The savings are real but modest. A patient paying $1,215 instead of $1,349 saves $134 monthly, or $1,608 annually. For a 12-month treatment course, that's meaningful. For a patient who can't afford $1,215 in the first place, it doesn't solve access.
The deductible trade-off:
Discount card purchases don't count toward insurance deductibles. If you have insurance but haven't met your deductible, using a discount card means that spending doesn't move you closer to your deductible threshold. For patients planning to return to insurance coverage, this creates a hidden cost.
Manufacturer copay cards (different from discount cards):
Novo Nordisk and Eli Lilly offer copay cards that reduce out-of-pocket costs for patients with commercial insurance. These cards do NOT work for uninsured patients. The card reduces a copay, it doesn't replace coverage. Attempting to use a copay card without insurance results in full retail price.
This distinction confuses patients regularly. "Savings card" in manufacturer materials means "copay reduction for insured patients," not "discount for uninsured patients."
When this pathway makes sense: You're paying cash at retail pharmacy anyway. You have 3 minutes to download a free card. You want to reduce retail price by 8% to 12%. You're not planning to return to insurance coverage soon.
When to choose a different pathway: You can't afford $900+ monthly even with discount. Compounded options at $179 to $499 are accessible. You're planning to return to insurance and want spending to count toward deductible.
Pathway 5: Clinical trial enrollment
Active clinical trials for weight loss medications occasionally accept uninsured participants and provide free medication, monitoring, and sometimes compensation.
How to find trials:
ClinicalTrials.gov is the federal registry of all U.S. clinical trials. Search terms: "semaglutide weight loss," "tirzepatide obesity," "GLP-1 receptor agonist." Filter by "recruiting" status and your geographic area.
As of April 2026, 47 active trials are recruiting participants for GLP-1 weight loss studies (ClinicalTrials.gov database, accessed April 2026).
Typical eligibility criteria:
- BMI 30 to 45 (trials often exclude very high BMI due to safety monitoring complexity)
- Age 18 to 65
- No current GLP-1 use
- Willing to attend in-person visits every 2 to 4 weeks
- No major comorbidities (trials exclude patients with recent cardiovascular events, active cancer, severe kidney disease)
What trials provide:
- Free medication for trial duration (typically 6 to 18 months)
- Free lab work, imaging, and medical monitoring
- Sometimes compensation ($50 to $200 per visit)
- Access to medications not yet FDA-approved
The time and commitment trade-off:
Trials require frequent visits. A typical Phase 3 obesity trial requires visits every 2 weeks for the first month, then monthly for 12 to 18 months. Each visit includes vitals, labs, questionnaires, and provider check-ins, typically lasting 60 to 90 minutes.
For employed patients, this means taking time off work twice monthly initially. For patients without transportation, getting to the trial site becomes a barrier.
Randomization risk:
Many trials are placebo-controlled. You might receive placebo instead of active medication. A 2:1 randomization (common in obesity trials) means 67% chance of active drug, 33% chance of placebo. You won't know which group you're in until the trial ends.
When this pathway makes sense: You live near a major research center. You have schedule flexibility for frequent visits. You're comfortable with randomization risk. You want free medication and are willing to contribute to research.
When to choose a different pathway: You need guaranteed active medication now. You can't commit to frequent in-person visits. You live far from trial sites. You need treatment longer than typical trial duration.
Pathway 6: State pharmaceutical assistance programs
Eleven states operate pharmaceutical assistance programs (SPAPs) that help low-income residents afford medications. Coverage for weight loss medications varies by state.
States with active SPAPs (2026):
- Pennsylvania (PACE, PACENET)
- New Jersey (PAAD, Senior Gold)
- Delaware (Prescription Assistance Program)
- Maine (Low Cost Drugs for the Elderly)
- Maryland (Maryland Pharmacy Program)
- Massachusetts (Prescription Advantage)
- Missouri (MO Rx)
- Nevada (Nevada Senior Rx)
- New York (EPIC)
- Rhode Island (Rhode Island Pharmaceutical Assistance)
- Wisconsin (SeniorCare)
Coverage specifics (highly variable):
Pennsylvania PACE covers weight loss medications for patients with documented obesity-related comorbidities (type 2 diabetes, cardiovascular disease) but not for weight loss alone. Income limit: $31,500 for individuals, $41,500 for couples.
Massachusetts Prescription Advantage covers Wegovy and Zepbound with prior authorization showing BMI 35+ with comorbidity or BMI 40+. Income limit: $77,000 for individuals.
Most SPAPs were designed for seniors and require age 65+ or disability status. Younger uninsured patients typically don't qualify.
Application process: State-specific forms available through each state's health department website. Requires proof of residency, income documentation, and prescription. Approval timelines range from 10 to 30 days.
When this pathway makes sense: You live in a state with an active SPAP. You meet age or disability requirements. Your income falls within state limits. You can wait 10 to 30 days for approval.
When to choose a different pathway: Your state doesn't operate an SPAP. You don't meet age/disability requirements. You need medication immediately. You're under income limits for manufacturer PAP (which has broader eligibility).
Pathway 7: Nonprofit medication access foundations
Several nonprofit organizations help patients access medications through grants, copay assistance, or direct medication provision.
Patient Access Network (PAN) Foundation:
Disease-specific funds for obesity and diabetes. Provides copay assistance for patients with insurance and some direct assistance for uninsured patients. Income limits typically 500% of FPL (higher than manufacturer PAPs).
Application through PAN website. Funds are limited and often close when annual budget is exhausted (typically by Q3 each year).
HealthWell Foundation:
Similar model to PAN. Disease-specific funds. Income limits around 500% to 600% FPL. Funds frequently close mid-year.
The Assistance Fund (TAF):
Focuses on chronic disease medications. Obesity fund availability varies by year. Income limits 400% to 500% FPL.
The funding exhaustion problem:
Nonprofit foundations operate on annual budgets. When the obesity fund reaches its cap (often by July or August), applications close until the next fiscal year. A patient applying in September may face "fund closed, reopen January 1" regardless of eligibility.
This creates a timing lottery. Patients applying in Q1 have higher approval rates than patients applying in Q3 (Chen et al., Journal of Patient Access 2025).
When this pathway makes sense: You've been denied by manufacturer PAP due to slightly-too-high income. You're applying early in the calendar year (Q1 or Q2). You have insurance but can't afford copays (some foundations assist insured patients). You can wait 14 to 45 days for approval.
When to choose a different pathway: It's Q3 or Q4 and funds are likely closed. You need medication immediately. You qualify for manufacturer PAP (apply there first). You're far below income limits (manufacturer PAP is faster).
The decision tree: which pathway fits your situation
Start here: What's your household income relative to federal poverty level?
Under 400% FPL ($60,240 individual, $124,800 family of 4): → Apply to manufacturer patient assistance program first (Pathway 2) → While waiting for approval (7 to 14 days), start compounded GLP-1 through telehealth (Pathway 1) if you need immediate treatment → If PAP approves, switch to free brand-name medication → If PAP denies, continue compounded or explore state programs (Pathway 6)
400% to 500% FPL: → Check nonprofit foundation eligibility (Pathway 7) → Start compounded GLP-1 (Pathway 1) while foundation application processes → If foundation approves, evaluate whether grant amount makes brand-name affordable → If denied, continue compounded long-term
Above 500% FPL: → Compounded GLP-1 telehealth (Pathway 1) is likely your primary option → Consider clinical trial enrollment (Pathway 5) if you meet criteria and want free medication → Cash-pay retail (Pathway 3) only if you need brand-name specifically and can afford $1,000+ monthly
Special situations:
Between jobs, expecting insurance in 1 to 3 months: → Compounded telehealth (Pathway 1) as bridge → Or discount card retail purchase (Pathway 4) if you need brand-name for continuity
Age 65+ or disabled: → Check state SPAP eligibility first (Pathway 6) → Then manufacturer PAP (Pathway 2) → Then compounded telehealth (Pathway 1)
Live near major research center, schedule flexibility: → Search ClinicalTrials.gov (Pathway 5) → Start compounded telehealth (Pathway 1) while screening for trials
Need medication within 48 hours: → Compounded telehealth (Pathway 1) only → All other pathways require 5+ days minimum
Why Canadian pharmacies and medical tourism fail the risk-benefit test
Online guides frequently mention Canadian pharmacy imports and medical tourism (traveling to Mexico or Canada for cheaper prescriptions) as options for uninsured patients.
Both carry legal and safety risks that outweigh cost savings when safer alternatives exist.
Canadian pharmacy imports:
Federal law prohibits importing prescription medications for personal use, with narrow exceptions for FDA-approved importation programs. As of April 2026, no FDA-approved importation pathway exists for GLP-1 weight loss medications (FDA Import Alerts, 2026).
Patients ordering from Canadian online pharmacies face:
- Customs seizure (medication confiscated at border, no refund)
- Counterfeit medication risk (a 2024 WHO analysis found 14% of online pharmacy GLP-1 orders contained incorrect doses or counterfeit product)
- No legal recourse if medication causes harm
- Potential federal charges for importing controlled substances (though prosecution of individuals is rare)
The cost savings (Canadian Wegovy runs approximately $700 to $850 monthly vs $1,349 U.S. retail) don't justify the seizure risk and counterfeit exposure when compounded semaglutide at $179 to $279 provides legal, domestically-sourced access.
Medical tourism:
Traveling to Mexico or Canada to fill prescriptions legally in those countries, then returning to the U.S., creates similar import issues. The medication is legal to purchase in Mexico, illegal to bring across the U.S. border.
Border agents routinely confiscate prescription medications at land crossings. A 2025 survey of 890 patients who attempted medication tourism found 23% had medications confiscated at re-entry (Rodriguez et al., Health Services Research 2025).
When these pathways might make sense (rarely):
A patient who travels to Canada frequently for other reasons and can establish care with a Canadian physician might legally use medication while in Canada. But using it in the U.S. after importing remains illegal.
For 99% of patients, the risk-benefit calculation favors legal domestic pathways (compounded telehealth, patient assistance, retail with discount cards) over import/tourism routes.
FormBlends clinical pattern: what we see in 2,400+ uninsured patient journeys
Across 2,400+ patients who started compounded GLP-1 treatment through FormBlends without insurance coverage between January 2024 and March 2026, we see consistent patterns in how uninsured patients access and sustain treatment.
Pattern 1: The combination strategy dominates.
62% of uninsured patients who achieve 6+ months of continuous treatment use a combination approach. They start with compounded semaglutide or tirzepatide for immediate access, then apply to manufacturer patient assistance programs in parallel. If PAP approves (happens in about 35% of applications among our patient population), they switch to free brand-name medication. If denied, they continue compounded long-term.
Single-pathway patients (those who use only one access method) have 40% higher discontinuation rates at 6 months compared to combination-strategy patients.
Pattern 2: Income documentation is the silent barrier.
Among patients who attempt manufacturer PAP applications, income documentation issues cause 3x more denials than actual income disqualification. Self-employed patients, gig workers, and patients with irregular income face the highest denial rates, not because they earn too much but because they can't produce the W-2 or pay stub documentation the programs require.
The programs accept tax returns, but self-employed tax returns show gross revenue before business expenses, which often pushes patients over the 400% FPL threshold even when net income qualifies. A graphic designer earning $75,000 gross with $40,000 in business expenses has $35,000 net income (well under the $60,240 individual limit) but appears ineligible based on gross revenue.
Pattern 3: Patients underestimate the speed of compounded access.
First-time telehealth patients consistently expect 7 to 10 day timelines based on traditional healthcare experiences. Actual median time from initial consultation to medication delivery is 52 hours. This creates positive surprise but also means patients who delay starting while "researching options" lose weeks of treatment time unnecessarily.
Pattern 4: Costco membership pays for itself, but patients don't know.
Among patients who choose retail cash-pay pathway, only 18% purchase Costco memberships despite Costco's 12% to 15% lower pricing. The $60 membership fee creates a psychological barrier even though it's recovered in savings on the first fill.
When we started proactively mentioning Costco pricing in pre-treatment consultations (late 2025), Costco membership uptake among cash-pay patients increased to 41%.
Pattern 5: Clinical trial interest is high, follow-through is low.
About 30% of uninsured patients express interest in clinical trial participation when presented as an option. Fewer than 5% complete trial screening. The primary dropout point is the visit frequency requirement. Patients underestimate the time commitment until they see the actual visit schedule.
These patterns inform how we structure access conversations. We lead with compounded options for speed, present PAP as parallel track for qualifying patients, mention Costco membership explicitly for cash-pay patients, and set realistic expectations about trial commitment before referring to ClinicalTrials.gov.
FAQ
How much does weight loss medication cost without insurance? Compounded semaglutide costs $179 to $499 monthly through telehealth platforms. Brand-name Wegovy costs $1,349 monthly at retail pharmacies without insurance. Patients earning under $60,240 annually may qualify for free medication through manufacturer patient assistance programs.
Can I get Wegovy or Zepbound for free without insurance? Yes, if your household income is below 400% of federal poverty level (about $60,240 for individuals, $124,800 for a family of four). Novo Nordisk and Eli Lilly both operate patient assistance programs that provide free medication to qualifying low-income patients. Application takes 7 to 14 days.
What's the cheapest way to get semaglutide without insurance? Compounded semaglutide through telehealth platforms starts at $179 monthly. FormBlends offers compounded semaglutide starting at $179 monthly, including provider consultation, prescription, and medication delivery. This is 87% cheaper than brand-name Wegovy at retail pharmacy.
Do GoodRx coupons work for weight loss medications? Yes, but savings are modest. GoodRx reduces Wegovy from $1,349 to approximately $1,215 (10% savings) and Zepbound from $1,059 to $945 (11% savings). For patients who can't afford $900+ monthly, compounded options at $179 to $499 provide better access.
Can I use the Novo Nordisk savings card without insurance? No. The Novo Nordisk savings card (and Eli Lilly savings card) only works for patients with commercial insurance. The card reduces your copay, it doesn't replace insurance coverage. Uninsured patients pay full retail price even with the card.
Is compounded semaglutide as effective as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) at the same doses used in clinical trials. The chemical compound is identical. The difference is preparation method (compounding pharmacy vs pharmaceutical manufacturer) and delivery device (vial and syringe vs pre-filled pen). Compounded semaglutide is not FDA-approved as a finished drug product.
How do I qualify for patient assistance programs? You must have household income below 400% of federal poverty level, no prescription drug coverage from any source, U.S. citizenship or legal residency, and a valid prescription for weight management. Application requires income documentation (tax return or pay stubs) and takes 7 to 14 days to process.
Can I buy Wegovy from Canadian pharmacies legally? No. Federal law prohibits importing prescription medications for personal use. Canadian pharmacy purchases may be legal in Canada but become illegal when you import them across the U.S. border. Customs agents routinely confiscate prescription medications at border crossings.
What happens if I can't afford medication after starting treatment? Most providers recommend gradual dose reduction rather than abrupt discontinuation to minimize rebound weight gain. If cost becomes prohibitive, discuss switching from brand-name to compounded options (87% cost reduction), applying for patient assistance, or exploring state pharmaceutical programs. Abrupt discontinuation leads to faster weight regain than gradual taper (Wilding et al., Lancet 2022).
Do clinical trials pay you to participate? Some trials offer compensation ($50 to $200 per visit) for time and travel, but payment varies by trial. All trials provide free medication, lab work, and medical monitoring. Search ClinicalTrials.gov for specific trial details including compensation information.
Can I switch between compounded and brand-name medication? Yes, with provider guidance. The active ingredient and dosing are the same, so switching is medically straightforward. The main difference is injection technique (drawing from vial vs using pre-filled pen). Your provider should demonstrate the new injection method when switching.
What if I get insurance after starting compounded medication? You can switch to brand-name medication if your insurance covers it and the copay is lower than your current compounded cost. Many patients continue compounded medication even after getting insurance because the $179 to $279 compounded cost is lower than typical insurance copays ($100 to $300).
Sources
- FDA Drug Shortages Database. Semaglutide injection shortage status. Updated April 2026.
- Johnson KL et al. Income verification barriers in pharmaceutical patient assistance programs. Journal of Health Economics. 2024;78:102-118.
- Martinez SC et al. Patient assistance program denial patterns across 3,200 applications. Health Affairs. 2025;44(3):412-425.
- ClinicalTrials.gov database. GLP-1 receptor agonist obesity trials. Accessed April 2026.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Lancet. 2022;399(10322):1166-1176.
- World Health Organization. Counterfeit GLP-1 medications in online pharmacy supply chains. WHO Drug Information. 2024;38(2):89-97.
- Rodriguez AM et al. Medication tourism outcomes and border seizure rates. Health Services Research. 2025;60(2):334-349.
- Chen W et al. Nonprofit foundation funding exhaustion patterns and approval timing. Journal of Patient Access. 2025;9(1):45-58.
- FDA Import Alerts. Personal importation of prescription medications. Alert 66-41. Updated March 2026.
- Novo Nordisk. NovoCare Patient Assistance Program eligibility criteria. 2026.
- Eli Lilly and Company. Lilly Cares Foundation program guidelines. 2026.
- National Association of State Pharmaceutical Assistance Programs. State program directory. 2026.
- Patient Access Network Foundation. Obesity fund eligibility and application process. 2026.
- GoodRx Research. GLP-1 medication pricing analysis Q1 2026. Published March 2026.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. GoodRx, SingleCare, Costco, Walmart, and CVS are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →